Skip to main content
AEON Biopharma, Inc. logo

AEON Biopharma, Inc. — Investor Relations & Filings

Ticker · AEON ISIN · US00775E1029 US Manufacturing
Open in API
Filings indexed 317 across all filing types
Latest filing 2022-05-12 Interim / Quarterly Rep…
Country US United States of America
Listing US AEON

About AEON Biopharma, Inc.

https://www.aeonbiopharma.com/

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused exclusively on developing therapeutic applications for botulinum toxins. The company is advancing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for the treatment of debilitating nervous system-related and neuromuscular disorders. Its lead clinical programs are investigating ABP-450 for the prevention of chronic and episodic migraines and the treatment of cervical dystonia. By concentrating solely on therapeutic indications, AEON aims to unlock the full potential of neurotoxins to provide lasting relief for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM10-Q
Interim / Quarterly Report Q1 2022
2022-05-12 English
FORM 10-K
Annual Report FY 2021
2022-03-28 English
FORM 8-K/A
Audit Report / Information Classification · 95% confidence The document is a Form 8-K/A filed with the SEC, which is an amendment to a previously filed Form 8-K. It specifically addresses a restatement of the company's audited balance sheet due to a classification error between temporary and permanent equity. The document includes detailed explanations about the restatement, its effects, and internal control considerations. It also references the original Form 8-K and includes an audited balance sheet as an exhibit. The content is focused on financial statement restatement and audit-related disclosures rather than a full annual report or quarterly report. Given the nature of the document as an amended current report focusing on audit and financial statement restatement, it fits best under the category of Audit Report / Information (AR). The document length (6249 characters) and detailed financial restatement content support this classification rather than a simple announcement or regulatory filing. Therefore, the filing type code is AR with high confidence.
2022-03-03 English
FROM 10-Q/A
Interim / Quarterly Report Q1 2021
2022-03-03 English
FORM 10-Q/A
Interim / Quarterly Report Q2 2021
2022-03-03 English
FORM 10-Q/A
Interim / Quarterly Report Q3 2021
2022-03-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.